Latest Information Update: 14 Feb 2015
At a glance
- Originator Servier
- Class Antineoplastics
- Mechanism of Action Proto-oncogene protein c-bcl-2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia; Myelodysplastic syndromes
Most Recent Events
- 01 Jan 2015 Phase-I clinical trials in Acute myeloid leukaemia (Monotherapy) in Australia and France (PO)
- 01 Jan 2015 Phase-I clinical trials in Myelodysplastic syndromes (Monotherapy, Second-line therapy or greater) in Australia and France (PO)